An Overview of the Natural History of Inflammatory Bowel Diseases

Domènech, Eugeni; Mañosa, Míriam; Cabré, Eduard

doi:10.1159/000358131

Cited by 44 publications

(33 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the majority of patients, only the rectum or the left colon is affected, resulting in rectal bleeding, diarrhoea, tenesmus and lower abdominal cramps. Notwithstanding that the disease has a mild‐to‐moderate course in the majority of patients, approximately 20%–25% develop at least one severe acute exacerbation requiring hospitalisation . Acute severe UC is a potentially life‐threatening condition that requires early recognition and timely intensive treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Notwithstanding that the disease has a mildto-moderate course in the majority of patients, approximately 20%-25% develop at least one severe acute exacerbation requiring hospitalisation. 2 Acute severe UC is a potentially life-threatening condition that requires early recognition and timely intensive treatment. A diagnosis of acute severe UC can be made using the modified criteria of Truelove and Witts, and is defined by the presence ≥6 bloody stools per day and at least one sign of systemic toxicity including a pulse rate >90 bpm, temperature >37.8°C, haemoglobin < 10.5 g/dL and/or an erythrocyte sedimentation rate >30 mm/h.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Hindryckx

Novak

Casteele

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Hindryckx

Novak

Casteele

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The medical treatment for ulcerative colitis is limited due to its complicated pathology. 2 Immunologic deficits, genetic background, stress, medical drug side effects, and irregular diet are reported as etiologic factors. Currently, the most frequently used drugs for ulcerative colitis are sulfasalazine and its derivatives, corticosteroids and immuno-suppressants.…”

mentioning

confidence: 99%

Methylene Blue Inhibits the Inflammatory Process of the Acetic Acid-Induced Colitis in Rat Colonic Mucosa

Dinç

Çaydere²,

Akgül³

et al. 2015

International Surgery

View full text Add to dashboard Cite

Inflammatory bowel disease is a serious health problem. Although it has been widely investigated, treatment of inflammatory bowel diseases currently remains as a challenging clinical problem. Over production of nitric oxide has been demonstrated to cause tissue damage and inflammation. In this study, the effect of methylene blue (MB), a well-known inhibitor of nitric oxide synthesis, was investigated in acetic acid (AA)-induced colitis model in Sprague-Dawley rats. Eighty male rats randomized into 4 groups (control, control MB, colitis, colitis + MB). AA was applied to groups 3 and 4. MB was added into group 2 and 4. Three days later, animals were sacrificed and 8 cm distal colonic segment resected and the specimens are examined using macroscopical, histological, and biochemical methods. The results of the macroscopic and microscopic examination showed that in group 4 the mucosal damage and inflammation score significantly lower than group 3. Increased intestinal permeability in acetic acid-administered group was significantly reversed by MB application. Myeloperoxidase activity and malondialdehyde levels increased significantly, while superoxide dismutase and catalase activities were suppressed after AA-administration. These biochemical parameters were reversed in MB-treated group. Administration of acetic acid resulted in increased levels of tumor necrosis factor-α, interleukin-1β, interleukin-6, total nitrite/nitrate levels and nitric oxide synthase activity. These biochemical alterations were significantly reversed by MB application also. In conclusion, our results indicate that MB decreases the level of nitric oxide and decreases inflammation in acetic acid-induced colitis.

show abstract

“…ASUC requiring hospitalisation occurs in 10%-25% at diagnosis and in 20%-30% during the disease course of ulcerative colitis. 5,6 Intravenous corticosteroids remain the cornerstone of first-line therapy for ASUC. A meta-analysis of cohort studies and randomised trials, published in 2007, examined the response to corticosteroids in ASUC.…”

Section: Introductionmentioning

confidence: 99%

Infliximab induction regimens in steroid‐refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis

Sebastian

Myers

Argyriou

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Accelerated induction regimens of infliximab have been proposed to improve response rates in patients with steroid‐refractory acute severe colitis. Aim To determine the differences in outcome for acute severe ulcerative colitis between accelerated and standard‐dose infliximab Methods We collected data on hospitalised patients receiving differing regimens of rescue therapy for steroid‐refractory acute severe ulcerative colitis. Our primary outcome was 30‐day colectomy rate. Secondary outcomes were colectomy within index admission, and at 90 days and 12 months. We used propensity score analysis with optimal calliper matching using high risk covariates defined a priori to reduce potential provider selection bias. Results We included 131 patients receiving infliximab rescue therapy; 102 received standard induction and 29 received accelerated induction. In the unmatched cohort, there was no difference by type of induction in the 30‐day colectomy rates (18% vs 20%, P = .45), colectomy during index admission (13% vs 20%, P = .26) or overall colectomy (20% vs 24%, P = .38). In the propensity score‐matched cohort of 52 patients, 30‐day colectomy (57% vs 27%, P = .048) and index admission colectomy (53% vs 23%, P = .045) rates were higher in those receiving standard induction compared to accelerated induction but there was no difference in overall colectomy rates (57% vs 31%, P = .09). There was no significant difference in length of stay or in complication and infection rates. Conclusion In a propensity score‐matched cohort, steroid‐refractory acute severe ulcerative colitis patients, short‐term, but not long‐term, colectomy rates appear to be lower in those receiving an accelerated induction regimen.

show abstract

An Overview of the Natural History of Inflammatory Bowel Diseases

Cited by 44 publications

References 29 publications

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Methylene Blue Inhibits the Inflammatory Process of the Acetic Acid-Induced Colitis in Rat Colonic Mucosa

Infliximab induction regimens in steroid‐refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis

Contact Info

Product

Resources

About